Rocket Pharmaceuticals Announces Proposed Public Offering of Common Stock
October 03 2022 - 4:42PM
Business Wire
Rocket Pharmaceuticals, Inc. (NASDAQ: RCKT), a leading
late-stage biotechnology company advancing an integrated and
sustainable pipeline of investigational genetic therapies for rare
childhood disorders with high unmet need, announced today that it
has commenced an underwritten public offering of $100 million of
shares of its common stock. Rocket also intends to grant the
underwriters a 30-day option to purchase up to an additional $15
million of shares of its common stock. All of the shares in the
proposed offering are to be sold by Rocket.
Morgan Stanley, J.P. Morgan and SVB Securities are acting as
joint book-running managers, and BTIG is acting as lead manager for
the proposed offering. The proposed offering is subject to market
and other conditions, and there can be no assurance as to whether
or when the offering may be completed, or as to the actual size or
terms of the offering.
The shares are being offered by Rocket pursuant to an effective
shelf registration statement that was previously filed with the
U.S. Securities and Exchange Commission (the “SEC”). The offering
is being made only by means of a written prospectus and prospectus
supplement that form a part of the registration statement. A
preliminary prospectus supplement relating to and describing the
terms of the offering will be filed with the SEC and will be
available on the SEC’s website at www.sec.gov.
When available, copies of the preliminary prospectus supplement
relating to the offering may also be obtained from Morgan Stanley
& Co. LLC, Attention: Prospectus Department, 180 Varick Street,
2nd Floor, New York, New York 10014, by telephone at (866)
718-1649, or by email at prospectus@morganstanley.com; J.P. Morgan
Securities LLC, c/o Broadridge Financial Solutions, 1155 Long
Island Avenue, Edgewood, New York 11717, by telephone at (866)
803-9204, or by email at prospectus-eqfi@jpmorganchase.com; or SVB
Securities LLC, Attention: Syndicate Department, 53 State Street,
40th Floor, Boston, MA 02109, by telephone at (800) 808-7525, ext.
6105, or by email at syndicate@svbsecurities.com.
The final terms of the offering will be disclosed in a final
prospectus supplement to be filed with the SEC.
This press release shall not constitute an offer to sell or a
solicitation of an offer to buy these securities, nor shall there
be any sale of these securities in any state or jurisdiction in
which such offer, solicitation or sale would be unlawful prior to
the registration or qualification under the securities laws of any
such state or jurisdiction.
About Rocket Pharmaceuticals, Inc.
Rocket Pharmaceuticals, Inc. (NASDAQ: RCKT) is advancing an
integrated and sustainable pipeline of investigational genetic
therapies designed to correct the root cause of complex and rare
childhood disorders. The Company’s platform-agnostic approach
enables it to design the best therapy for each indication, creating
potentially transformative options for patients afflicted with rare
genetic diseases. Rocket's clinical programs using lentiviral
vector (LVV)-based gene therapy are for the treatment of Fanconi
Anemia (FA), a difficult to treat genetic disease that leads to
bone marrow failure and potentially cancer, Leukocyte Adhesion
Deficiency-I (LAD-I), a severe pediatric genetic disorder that
causes recurrent and life-threatening infections which are
frequently fatal, and Pyruvate Kinase Deficiency (PKD), a rare,
monogenic red blood cell disorder resulting in increased red cell
destruction and mild to life-threatening anemia. Rocket’s first
clinical program using adeno-associated virus (AAV)-based gene
therapy is for Danon Disease, a devastating, pediatric heart
failure condition.
Rocket Cautionary Statement Regarding Forward-Looking
Statements
Various statements in this release concerning the timing, size
and completion of the proposed public offering on the anticipated
terms or at all may constitute forward-looking statements for the
purposes of the safe harbor provisions under the Private Securities
Litigation Reform Act of 1995, as amended, and other federal
securities laws. All such forward-looking statements are based on
management’s current expectations of future events and are subject
to a number of substantial risks and uncertainties, many of which
are outside Rocket’s control, that could cause actual results to
differ materially and adversely from those set forth in or implied
by such forward-looking statements. These risks and uncertainties
include fluctuations in Rocket’s stock price, changes in market
conditions, the final terms of the public offering and satisfaction
of customary closing conditions related to the public offering, as
well as those risks more fully discussed in the section entitled
"Risk Factors" in the prospectus supplement and registration
statement referenced above, Rocket’s Annual Report on Form 10-K for
the year ended December 31, 2021, filed February 28, 2022 with the
SEC and subsequent filings with the SEC including our Quarterly
Reports on Form 10-Q and Current Reports on Form 8-K. There can be
no assurance that Rocket will be able to complete the public
offering on the anticipated terms. Accordingly, you should not
place undue reliance on these forward-looking statements. All such
statements speak only as of the date made, and Rocket undertakes no
obligation to update or revise publicly any forward-looking
statements, whether as a result of new information, future events
or otherwise, unless required by law.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20221003005999/en/
Media Kevin Giordano Director, Corporate Communications
kgiordano@rocketpharma.com Investors Jessie Yeung, M.B.A.
Vice President, Investor Relations and Corporate Finance
investors@rocketpharma.com
Rocket Pharmaceuticals (NASDAQ:RCKT)
Historical Stock Chart
From Mar 2024 to Apr 2024
Rocket Pharmaceuticals (NASDAQ:RCKT)
Historical Stock Chart
From Apr 2023 to Apr 2024